Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Molecular Landscape of Chronic Lymphocytic Leukemia Using Targeted Gene Panel Sequencing

Agnes Mosolygo-Lukacs, Maria Balogh, Lajos Gergely, Laszlo Rejto, Robert Szasz, Aniko Ujfalusi

Blood (2022) 140 (Supplement 1): 4993–4994.

https://doi.org/10.1182/blood-2022-157284

Published: 2022

Journal Articles

Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers

Virág Réka Szita, MD, Gábor Mikala, MD PhD, János Fábián, MD, Péter Rajnics, MD PhD, László Rejtő, MD PhD, Tamás Szendrei, MD, Hussain Alizadeh, MD PhD DSc, Laszlo Varoczy, MD PhD, Árpád Illés, MD PhD, Tamas Masszi, MD PhD, Gergely Varga, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-139870

Published: 2020

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

https://doi.org/10.1182/blood-2019-128022

Published: 2019

Journal Articles

Retrospective Comparison Of Autologous Transplantation Results Of Decreased MNC Viability Graft Cases (n=52) To Good Viability Graft Cases (n=306), a Single Centre Experience

Mariann Szarvas, Gabriella Kovács, Zita Korondán, Peter Batar, MD, PhD, Attila Kiss, MD, PhD, László Rejtö, MD, PhD, Gyula Reményi, MD, Róbert Szász, MD, László Váróczy, MD, PhD, Árpád Illés, MD, PhD, DSc, Miklós Udvardy, MD, PhD, DSc

Blood (2013) 122 (21): 2164.

https://doi.org/10.1182/blood.V122.21.2164.2164

Published: 2013

Journal Articles

The Effect of Bortezomib Containing Induction On the Long Term Outcome of autologous Haemopoietic Stem Cell Transplantation in Multiple Myeloma Patients Outside Clinical Trials - a Single Center Experience

Miklos Udvardy, MD, PhD, Remenyi Gyula, Attila Kiss, Prof. Dr., Peter Batar, Dr, Arpad Illes, MD, PhD, Dsc, Laszló Varoczy, MD PhD, Gaspar Radvanyi, MD, Robert Szasz, PhD, MD, Laszlo Rejto, PhD, MD

Blood (2012) 120 (21): 5050.

https://doi.org/10.1182/blood.V120.21.5050.5050

Published: 2012

Journal Articles

A New Approach to Predict the Chance of Infectious Complications Following Autologous Hematopoietic Stem Cell Transplantation: Mannose-Binding Lectin ELISA

Zita Radnay, MD, Miklos Udvardy, PhD, MD, Attila Kiss, PhD, MD, Maria Papp, PhD, MD, Laszlo Rejto, PhD, MD, Jolan Harsfalvi, PhD, Tamas Masszi, MD, PhD, Robert Szasz, PhD, MD, Peter Batar, MD, PhD, Gyula Remenyi, MD, Bela Telek, PhD, MD

Blood (2011) 118 (21): 4492.

https://doi.org/10.1182/blood.V118.21.4492.4492

Published: 2011

Journal Articles

Bortezomib+Chemotherapy Based Salvage Combinations in Refractory AML, Preliminary Results

Miklos Udvardy, Attila Kiss, Bela Telek, Robert Szasz, Peter Batar, Gyula Remenyi, Andrew Cakana, Laszlo Rejto

Blood (2008) 112 (11): 4000.

https://doi.org/10.1182/blood.V112.11.4000.4000

Published: 2008

NARROW

Molecular Landscape of Chronic Lymphocytic Leukemia Using Targeted Gene Panel Sequencing

Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Retrospective Comparison Of Autologous Transplantation Results Of Decreased MNC Viability Graft Cases (n=52) To Good Viability Graft Cases (n=306), a Single Centre Experience

The Effect of Bortezomib Containing Induction On the Long Term Outcome of autologous Haemopoietic Stem Cell Transplantation in Multiple Myeloma Patients Outside Clinical Trials - a Single Center Experience

A New Approach to Predict the Chance of Infectious Complications Following Autologous Hematopoietic Stem Cell Transplantation: Mannose-Binding Lectin ELISA

Bortezomib+Chemotherapy Based Salvage Combinations in Refractory AML, Preliminary Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only